| LUCIANI, M, L BOMGAARS, E CHALMERS, Leslie MITCHELL, I NURMEEV, A SHARATHKUMAR, P SVIRIN, K GORBATIKOV, I TARTAKOVSKY, M SIMETZBERGER, F HUANG, Z SUN, J KREUZER, S GROPPER, P REILLY, M BRUECKMANN a Tomáš KUHN. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol. 2021, roč. 8, č. 1, s. e22-e33. ISSN 2352-3026. Dostupné z: https://dx.doi.org/10.1016/S2352-3026(20)30368-9. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1790730,
author = {Luciani, M and Bomgaars, L and Chalmers, E and Mitchell, Leslie and Nurmeev, I and Sharathkumar, A and Svirin, P and Gorbatikov, K and Tartakovsky, I and Simetzberger, M and Huang, F and Sun, Z and Kreuzer, J and Gropper, S and Reilly, P and Brueckmann, M and Kuhn, Tomáš and Kuhn, Tomáš},
article_number = {1},
doi = {http://dx.doi.org/10.1016/S2352-3026(20)30368-9},
language = {eng},
issn = {2352-3026},
journal = {Lancet Haematol},
title = {Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial},
volume = {8},
year = {2021}
}
TY - JOUR
ID - 1790730
AU - Luciani, M - Bomgaars, L - Chalmers, E - Mitchell, Leslie - Nurmeev, I - Sharathkumar, A - Svirin, P - Gorbatikov, K - Tartakovsky, I - Simetzberger, M - Huang, F - Sun, Z - Kreuzer, J - Gropper, S - Reilly, P - Brueckmann, M - Kuhn, Tomáš - Kuhn, Tomáš
PY - 2021
TI - Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial
JF - Lancet Haematol
VL - 8
IS - 1
SP - e22-e33
EP - e22-e33
SN - 23523026
ER -
LUCIANI, M, L BOMGAARS, E CHALMERS, Leslie MITCHELL, I NURMEEV, A SHARATHKUMAR, P SVIRIN, K GORBATIKOV, I TARTAKOVSKY, M SIMETZBERGER, F HUANG, Z SUN, J KREUZER, S GROPPER, P REILLY, M BRUECKMANN a Tomáš KUHN. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. \textit{Lancet Haematol}. 2021, roč.~8, č.~1, s.~e22-e33. ISSN~2352-3026. Dostupné z: https://dx.doi.org/10.1016/S2352-3026(20)30368-9.
|
